Hudson Bay Capital Management Boosts Stake in Vera Therapeutics

Institutional investor increases holdings in biotech company by 47.4% in Q3

Mar. 20, 2026 at 9:37am

Got story updates? Submit your updates here. ›

Hudson Bay Capital Management LP, a prominent investment firm, has increased its stake in Vera Therapeutics, Inc. (NASDAQ:VERA) by 47.4% during the third quarter. The fund now owns 440,591 shares of the biotech company's stock, representing 0.69% ownership.

Why it matters

Vera Therapeutics is a clinical-stage biotech focused on developing novel immunotherapies for autoimmune and inflammatory diseases. Hudson Bay's increased investment signals confidence in the company's pipeline and future growth potential.

The details

According to a recent SEC filing, Hudson Bay Capital Management acquired an additional 141,615 shares of Vera Therapeutics during Q3 2026. The firm now holds a total of 440,591 shares, worth approximately $12.8 million based on the stock's current trading price. This represents a 47.4% increase in Hudson Bay's position in the company.

  • Hudson Bay Capital Management increased its stake in Vera Therapeutics during the 3rd quarter of 2026.

The players

Hudson Bay Capital Management LP

A prominent investment management firm that has increased its stake in Vera Therapeutics by 47.4%.

Vera Therapeutics, Inc.

A clinical-stage biotech company focused on developing novel immunotherapies for autoimmune and inflammatory diseases.

Got photos? Submit your photos here. ›

The takeaway

Hudson Bay Capital's increased investment in Vera Therapeutics suggests the firm sees significant growth potential in the biotech company's pipeline and future prospects. This vote of confidence from a major institutional investor could signal positive momentum for Vera Therapeutics as it continues to advance its immunotherapy programs.